The cost and safety of multidose use of palivizumab vials

Clinical Pediatrics

Volumn 47, Issue 2, 2008, Pages 160-163

  Gooding, Julie ^a   Millage, Aaron ^c   Rye, Anna Kathryn ^c   Lacroix, Robin ^b  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b Pediatric Infectious Disease   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cost savings; Immunizations; Prematurity; Respiratory syncytial virus; RSV

Indexed keywords

PALIVIZUMAB;

ARTICLE; BACTERIAL GROWTH; BACTERIUM CONTAMINATION; COST CONTROL; CULTURE TECHNIQUE; DRUG COST; DRUG SAFETY; HUMAN; INCIDENCE; REPEATED DRUG DOSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG CONTAMINATION; DRUG PACKAGING; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SAFETY;

EID: 38849106272     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922807306994     Document Type: Article

References (16)

1. Behrman RE, Kliegman RM, Jenson HB Nelson Textbook of Pediatrics. 1 7 th ed. Philadelphia, Pa: Saunders ; 2004.
2. Centers for Disease Control. Available at: www.cdc.gov/ncidod/dvrd/revb/ respiratory/rsvfeat.htm. Accessed July 15, 2006.
3. Institute of Medicine. Prospects for immunizing against respiratory syncytial virus (1Appendix N). New Vaccine Development: Establishing Priorities: Diseases of Importance in the United States. Washington, DC: National Academy Press ; 1985 ; 397-409.
4. Romero JR Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr Infect Dis J. 2003 ; 22: S46 - S54.
5. Oh PI, Lanctot KL, Yoon A., et al. Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada: Utilization and Outcomes. Pediatr Infect Dis J. 2002 ; 21: 512-518.
6. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1988 ; 102: 531-537.
7. Pedraz C., Carbonell-Estrany X., Figueras-Aloy J., Quero J., Iris Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J. 2003 ; 22: 823-837.
8. Moler FW, Brown RW, Faix RG, Gilsdorf JR Comments of palivizumab (Synagis). Pediatrics. 1999 ; 103: 495-496.
9. Wegner S., Vann JJ, Liu G., et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics. 2004 ; 114: 1612-1619.
10. World Health Organization. WHO Policy Statement: The Use of Opened Multi-Dose Vials of Vaccine in Subsequent Immunization Sessions. March 2000. Available at: http:// www.who.int/vaccines-documents/DocsPDF99/www9924.pdf. Accessed July 15, 2006.
11. Meissner HC, Anderson LJ, Pickering LK Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab. Pediatrics. 2004 ; 114: 1082-1084.
12. Silverman W. A health care management company's experience with palivizumab-1 year later. Manage Care. 2003: 12: 49-50.
13. Meissner HC, Long SS, Committee on Infectious Diseases, Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003 ; 112: 1447-1452.
14. Strutton DR, Stang PE Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making. J Pediatr. 2003 ; 143: S157 - S162.
15. Helm EA, Cummings GE, Keane V., King JC Administration of palivizumab: a medical provider's prospective. Clin Pediatr. 2003 ; 42: 821-826.
16. Christenson EA, Mordhorst CH, Jepsen OB Assessment of risk of microbial contamination by use of multidose containers of injectable products. J Hosp Infect. 1992 ; 20: 301-304.